EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung ...

The Employees’ Provident Fund Organisation (EPFO) has extended the deadline for activating the Universal Account Number (UAN) and linking it with Aadhaar to January 15, 2025. This extension ...

PubMatic has announced that its media activation platform, Activate has achieved nearly 6x growth in customer count and nearly 5x in campaign count year-over-year in 2024. All “Big Six ...

The Employees’ Provident Fund Organisation (EPFO) has extended the deadline to January 15, 2025, for activating the Universal Account Number (UAN) and linking it with a bank account and Aadhaar ...